Evidence based contraceptive choices

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 20, Issue 5, 2006, Pages 665-680

  Scott, Alison ^a   Glasier, Anna ^a  

^a Family Planning and Well Woman Services   (United Kingdom)

Author keywords

barrier; contraception; fertility; hormonal; implants; intrauterine; sterilisation

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CONTRACEPTIVE AGENT; COPPER INTRAUTERINE DEVICE; DESOGESTREL; DIANE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ELCOMETRINE; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETONOGESTREL; GESTAGEN; GESTODENE; GONADORELIN AGONIST; INJECTABLE CONTRACEPTIVE AGENT; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; NORETHISTERONE ENANTATE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT;

ACNE; ACNE VULGARIS; AMENORRHEA; ANOREXIA; BODY WEIGHT DISORDER; BONE DENSITY; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLON CANCER; CONDOM; CONTRACEPTION; CULTURAL FACTOR; DRUG BLOOD LEVEL; DRUG POTENTIATION; DYSMENORRHEA; ENDOMETRIOSIS; ENDOMETRIUM CANCER; EVIDENCE BASED PRACTICE; FAMILY PLANNING; FEMALE STERILIZATION; FLUID RETENTION; HEADACHE; HEART INFARCTION; HIRSUTISM; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LIBIDO DISORDER; MALE STERILIZATION; MEDICAL DECISION MAKING; MENSTRUATION DISORDER; META ANALYSIS; MOOD DISORDER; NAUSEA; OSTEOPOROSIS; OVARY CANCER; PELVIC INFLAMMATORY DISEASE; PREGNANCY RATE; PRIORITY JOURNAL; REPRODUCTIVE HEALTH; REVIEW; RISK ASSESSMENT; SEXUAL BEHAVIOR; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TRANSDERMAL PATCH; UTERINE CERVIX CAP; VAGINA BLEEDING; VAGINA RING; VASECTOMY; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

CHOICE BEHAVIOR; CONTRACEPTION; CONTRACEPTION BEHAVIOR; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE DEVICES, FEMALE; COUNSELING; DECISION MAKING; EVIDENCE-BASED MEDICINE; FAMILY PLANNING SERVICES; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; MALE; STERILIZATION, REPRODUCTIVE;

EID: 33749239834     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2006.03.002     Document Type: Review

References (59)

1. Population Reference Bureau. 2003 World Population Data Sheet. Available at: (2003). www.prb.org
2. Piccinino L.J., and Mosher W.D. Trends in contraceptive use in the United States: 1982-1995. Family Planning Perspectives 30 (1998) 4-10 46
3. Dawe F., and Rainford L. Contraception and Sexual Health 2003. A report on research using the ONS Omnibus Survey produced by the Office for National Statistics on behalf of the Department of Health, London (2004), Office for National Statistics, London
4. Bajos N., Leridon H., Gowlard H., et al., the COCON Group. Contraception: from accessibility to efficiency. Human Reproduction 18 (2003) 994-999
5. Oddens B.J., and Milsom I. Contraceptive practice and attitudes in Sweden 1994. Acta Obstetricia et Gynecologica Scandinavica 75 (1996) 932-940
6. Rosenberg M.J., and Waugh M.S. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. American Journal of Obstetrics and Gynecology 179 (1998) 577-582
7. WHO. Medical Eligibility Criteria for Contraceptive Use. 3rd edn. (2004), WHO, Geneva. Available at: www.who.int/reproductive-health/publications/MEC_3/mec.pdf
8. Dawe F., and Meltzer H. Contraception and Sexual Health 2002. National Statistics, pp 1-49 (2003), HMSO, London. Available at: www.statistics.gov.uk
9. Rivera R., Yacobson I., and Grimes D. The mechanism of action of hormonal contraceptive and intrauterine contraceptive devices. American Journal of Obstetrics and Gynecology 181 (1999) 1263-1269
10. FFPRHC Guidance. The levonorgestrel-releasing intrauterine system (LNG-IUS) in contraception and reproductive health. The Journal of Family Planning and Reproductive Health Care 30 (2004) 99-109
11. Sivin I., Stern J., Continho E., et al. Prolonged intrauterine contraception: a seven year randomised study of levonorgestrel 20 μg (LNG 20) and copper T380 Ag IUD. Contraception 44 (1991) 473-480
12. Baldaszti E., Wimmer-Puchinger B., and Loschke K. Acceptability of long term contraceptive levonorgestrel releasing intrauterine system (Mirena): a 3 year follow-up study. Contraception 67 (2003) 87-91
13. Hidalgo M., Bahamondes L., Perotti M., et al. Bleeding patterns and clinical performance of the levonorgestrel releasing intrauterine system (Mirena) up to 2 years. Contraception 65 (2002) 129-132
14. Zhang J., Feldblum P.J., Chi I.C., and Farr M.G. Risk factors for copper IUD expulsion: an epidemiologic analysis. Contraception 46 (1992) 427-433
15. FFPRHC Guidance. The copper intrauterine device as long-term contraception. The Journal of Family Planning and Reproductive Health Care 30 (2004) 29-42
16. Hubacher D., Lara-Ricalde R., Taylor D.J., et al. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. The New England Journal of Medicine 345 (2001) 561-567
17. Agrawal A., and Robinson C. An assessment of the first 3 years' use of Implanon in Luton. The Journal of Family Planning and Reproductive Health Care 31 (2005) 310-312
18. Glasier A. Implantable contraceptives for women: effectiveness, discontinuation rates, return of fertility and outcome of pregnancies. Contraception 65 (2002) 29-37
19. Davies G.C., Li X.F., Newton J.R., et al. Release characteristics, ovarian activity and menstrual bleeding with a single contraceptive implant releasing 3-ketodesogestrel. Contraception 47 (1993) 251-261
20. Singh K., Viegas O.A., and Ratnam S.S. Norplant contraceptive implants - a comparison of capsules versus rods in Singapore. Singapore Medical Journal 31 (1990) 568-572
21. Beerthuizen R., van Beek A., Massai R., et al. Bone mineral density during long term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception. Human Reproduction 15 (2002) 118-122
22. Mishell Jr. D.R. Injectable contraception. The Journal of Reproductive Medicine 47 (2002) 777-779
23. Westhoff C. Depot-medroxyprogesterone acetate injection (Depo Provera): a highly effective contraceptive option with proven long term safety. Contraception 68 (2003) 75-87
24. Scholes D., LaCroix A.Z., Ichikawa L.E., et al. Change in bone mineral density among adolescent women using and discontinuing depo-medroxyprogesterone acetate contraception. Archives of Pediatrics & Adolescent Medicine 159 (2005) 139-144
25. CSM Depo statement. Updated prescribing advice on the effect of Depo Provera on bones. Nov 2004. Available at: www.mhra.gov.uk.
26. Dawe F., and Meltzer H. Contraception and Sexual Health 2001 (2003), Office for National Statistics, London
27. Maudsley R.F., and Qizilbah A.H. Thermal injury to the bowel as a complication of laparoscopic sterilisation. Canadian Journal of Surgery 22 (1979) 232-234
28. Kerrin J.F., Carignan C.S., and Cher D. The safety and effectiveness of a new hysteroscopic method for permanent birth control: results of the first ESSURE pbc clinical study. The Australian & New Zealand Journal of Obstetrics & Gynaecology 41 (2001) 364-370
29. Peterson H.B., Xia Z., Hughes J.M., et al. The risk of pregnancy after tubal sterilisation: findings for the United States Collaborative Review of Sterilisation. American Journal of Obstetrics and Gynecology 174 (1996) 1161-1168
30. Hillis S.D., Marchbanks P.A., Tylor L.R., and Peterson H.B. Poststerilisation regret: findings from the United States Collaborative Review of Sterilisation. Obstetrics and Gynecology 93 (1999) 889-895
31. Royal College of Obstetricians and Gynaecologists (RCOG). Male and female sterilisation. Evidence-based Clinical Guidelines No 4. 2nd edn. (2004), RCOG, London
32. Cook L.A., Vliet H., Pun A., and Gallo M.F. Vasectomy occlusion techniques for male sterilisation. Cochrane Database Systematic Reviews 3 (2004) CD003991. Available at: www.thecochranelibrary.com
33. Smith A.G., Crooks J., Singh N.P., et al. Is the timing of post-vasectomy seminal analysis important?. British Journal of Urology 81 (1998) 458-460
34. Cox B., Sneyd M.J., Paul C., et al. Vasectomy and risk of prostate cancer. JAMA: The Journal of the American Medical Association 287 (2002) 3110-3115
35. Moller H., Knudsen L.B., and Lynge E. Risk of testicular cancer after vasectomy: cohort study of over 73,000 men. British Medical Journal 309 (1994) 295-299
36. McMahon A.J., Buckley J., Taylor A., et al. Chronic testicular pain following vasectomy. British Journal of Urology 69 (1992) 188-191
37. Centers for Disease Control and Prevention. Facts About Condoms and Their Use in Preventing HIV Infection and Other STDs (1995), CDC, Atlanta
38. Gallo M.F., Grimes D.A., and Schulz K.F. Nonlatex vs latex male condoms for contraception: a systematic review of randomised controlled trials. Contraception 68 (2003) 319-326
39. Cook L., Nanda K., and Grimes D. Diaphragm versus diaphragm with spermicides for contraception. Cochrane Database Systematic Reviews 1 (2003) CD002031. Available at: www.thecochranelibrary.com
40. Raymond E.G., Chen P.L., Luoto J., and Spermicide Trial Group. . Contraceptive effectiveness and safety of five nonoxynol-9 spermicides: a randomised trial. Obstetrics and Gynecology 103 (2004) 430-439
41. Flynn A.M. Natural methods of family planning. Clinics in Obstetrics and Gynaecology 11 (1984) 661-678
42. Labbok M., Koniz-Booker P., Cooney K., et al. Guidelines for Breastfeeding in Family Planning and Child Survival Programs 1990 (1990), Institute for Studies in NFP, Washington, DC
43. Croft P., and Hannaford P. Risk factors for myocardial infarction in women - evidence from RCGP Oral Contraceptive Study. British Medical Journal 298 (1989) 165-168
44. World Health Organization. WHO Collaborative study of Cardiovascular Disease and Sex Steroid Hormone Contraception. Ischaemic stroke and combined oral contraception: results of an international, multicentre, case-control study. Lancet 348 (1996) 498-505
45. World Health Organization. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen containing oral contraceptives on venous thromboembolism. Lancet 346 (1995) 1575-1582
46. FFPRHC Guidance. First prescription of combined oral contraception. The Journal of Family Planning and Reproductive Health Care 29 (2003) 209-223
47. Vessey M., Painter R., and Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet 362 (2003) 185-191
48. Colditz G.A. Oral contraceptive use and mortality during 12 years of follow-up: the Nurses Health Study. Annals of Internal Medicine 120 (1994) 821-826
49. Beral V., Hermon C., Kay C., et al. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46,000 women from the Royal College of General Practitioners' oral contraception study. British Medical Journal 318 (1999) 96-100
50. Hendrix S.L., and Alexander N.J. Primary dysmenorrhoea treatment with a desogestrel-containing low dose oral contraceptive. Contraception 66 (2002) 393-399
51. Iyer V., Farquhar C., and Jepson R. Oral contraceptive pills for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2 (1997) CD000154. Available at: www.thecochranelibrary.com
52. Moore J., Kennedy S., and Prentice A. Modern combined oral contraceptive for pain associated with endometriosis. Cochrane Database of Systematic Reviews 4 (1997) CD001019. Available at: www.thecochranelibrary.com
53. International Agency for Research on Cancer (IARC). Monographs on the Evaluation of Carcinogenic Risks to Humans. Hormonal Contraception and Postmenopausal Hormonal Therapy (1999), WHO IARC, Lyons, France
54. Lanes S.F., Birman B., Walker A.M., et al. Oral contraceptive type and functional ovarian cysts. American Journal of Obstetrics and Gynecology 166 (1992) 956-961
55. Cancer and Steroid Hormones (CASH). Combined oral contraceptive use and risk of endometrial cancer. JAMA: The Journal of the American Medical Association 257 (1987) 796-800
56. Fernandez E., Vecchia C.L., Balducci A., et al. Oral contraceptives and colorectal cancer risk: a meta-analysis. British Journal of Cancer 84 (2001) 722-727
57. Michaelsson K., Baron J.A., Farahmand B.Y., et al. Oral contraceptive use and risk of hip fracture: case control study. Lancet 353 (1999) 1481-1484
58. Rosen M.P., Breitkopf D.M., and Nagamani M. A randomized controlled trial of second versus third generation oral contraceptive treatment of acne vulgaris. American Journal of Obstetrics and Gynecology 188 (2003) 1158-1160
59. Audet M.C., Morean M., Koltun W.D., et al., for the ORTHO/EVRA study group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive. A randomized controlled trial. JAMA: The Journal of the American Medical Association 285 (2001) 2347-2354